Top Ad unit 728 × 90

Radiology News


Radium 223-Update

NEJM (N Engl J Med 2013; 369:276-278)  latest issue, Vapiwala et al report : Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles in men with castration-resistant prostate cancer and bone metastases. Radium-223 dichloride (radium-223), the first alpha emitter to undergo phase 3 testing and receive approval for clinical use, acts independently of cell cycles, surface markers, and tumor types. The simplicity of the alpha emitter radium-223 lies in its winning combination of a convenient half-life (11.4 days) and its inherent bone-seeking and potent DNA-damaging properties. 
Radium 223-Update Reviewed by Sumer Sethi on Friday, July 19, 2013 Rating: 5

No comments:

All Rights Reserved by Sumer's Radiology Blog © 2014 - 2015
Powered By Blogger,

Contact Form


Email *

Message *

All contents copyrights with Sumer Sethi. Powered by Blogger.